Skip to main content

Volume 9 Supplement 3

Proceedings of the 2007 and 2008 Drug Discovery for Neurodegeneration Conference


Edited by Howard Fillit and Antony Horton

The conference and the publication of these proceedings were supported by a conference grant: U13-AG031125 from the National Institute of Aging and the National Institute for Neurological Disorders and Stroke. Additional support was provided by CoMentis, Inc; Pfizer, Inc.; Biogen Idec and Boehringer Ingelheim Pharmaceuticals, Inc.

2007 and 2008 Drug Discovery for Neurodegeneration Conference. Go to conference site.

New York, USA. 5-6 February 2007Washington, DC, USA. 4-5 February 2008

  1. Intranasal delivery provides a practical, non-invasive method of bypassing the blood-brain barrier (BBB) to deliver therapeutic agents to the brain and spinal cord. This technology allows drugs that do not cro...

    Authors: Leah R Hanson and William H Frey II
    Citation: BMC Neuroscience 2008 9(Suppl 3):S5
  2. This short review outlines the rationale, challenges, and opportunities for intranasal acetylcholinesterases, in particular galantamine. An in vitro screening model facilitated the development of a therapeuticall...

    Authors: Henry R Costantino, Alexis Kays Leonard, Gordon Brandt, Paul H Johnson and Steven C Quay
    Citation: BMC Neuroscience 2008 9(Suppl 3):S6

Annual Journal Metrics

  • 2022 Citation Impact
    2.4 - 2-year Impact Factor
    3.3 - 5-year Impact Factor
    0.824 - SNIP (Source Normalized Impact per Paper)
    0.688 - SJR (SCImago Journal Rank)

    2023 Speed
    21 days submission to first editorial decision for all manuscripts (Median)
    136 days submission to accept (Median)

    2023 Usage 
    1,031 Altmetric mentions 

Sign up for article alerts and news from this journal